DZ2954A1 - Antagoniste des recepteurs de vitronectine, procédé pour sa préparation et compositions pharmaceutiques le contenant. - Google Patents

Antagoniste des recepteurs de vitronectine, procédé pour sa préparation et compositions pharmaceutiques le contenant.

Info

Publication number
DZ2954A1
DZ2954A1 DZ990254A DZ990254A DZ2954A1 DZ 2954 A1 DZ2954 A1 DZ 2954A1 DZ 990254 A DZ990254 A DZ 990254A DZ 990254 A DZ990254 A DZ 990254A DZ 2954 A1 DZ2954 A1 DZ 2954A1
Authority
DZ
Algeria
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
receptor antagonist
vitronectin receptor
Prior art date
Application number
DZ990254A
Other languages
English (en)
Inventor
William H Miller
Peter J Manley
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DZ2954A1 publication Critical patent/DZ2954A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
DZ990254A 1998-12-04 1999-12-01 Antagoniste des recepteurs de vitronectine, procédé pour sa préparation et compositions pharmaceutiques le contenant. DZ2954A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11090398P 1998-12-04 1998-12-04

Publications (1)

Publication Number Publication Date
DZ2954A1 true DZ2954A1 (fr) 2004-06-20

Family

ID=22335565

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990254A DZ2954A1 (fr) 1998-12-04 1999-12-01 Antagoniste des recepteurs de vitronectine, procédé pour sa préparation et compositions pharmaceutiques le contenant.

Country Status (39)

Country Link
US (1) US6495560B1 (fr)
EP (1) EP1146874B1 (fr)
JP (1) JP4481504B2 (fr)
KR (1) KR100620485B1 (fr)
CN (1) CN1147300C (fr)
AP (1) AP1534A (fr)
AR (1) AR035006A1 (fr)
AT (1) ATE277043T1 (fr)
AU (1) AU754408B2 (fr)
BG (1) BG65118B1 (fr)
BR (1) BR9915879A (fr)
CA (1) CA2353415A1 (fr)
CO (1) CO5150166A1 (fr)
CZ (1) CZ20011963A3 (fr)
DE (1) DE69920518T2 (fr)
DK (1) DK1146874T3 (fr)
DZ (1) DZ2954A1 (fr)
EA (1) EA003254B1 (fr)
EG (1) EG24025A (fr)
ES (1) ES2229798T3 (fr)
HK (1) HK1042037B (fr)
HU (1) HUP0104804A3 (fr)
ID (1) ID28811A (fr)
IL (2) IL143390A0 (fr)
MA (1) MA25265A1 (fr)
NO (1) NO318895B1 (fr)
NZ (1) NZ511876A (fr)
OA (1) OA11724A (fr)
PE (1) PE20001563A1 (fr)
PL (1) PL195973B1 (fr)
PT (1) PT1146874E (fr)
SI (1) SI1146874T1 (fr)
SK (1) SK7452001A3 (fr)
TR (1) TR200101654T2 (fr)
TW (1) TW482673B (fr)
UA (1) UA71586C2 (fr)
UY (1) UY25824A1 (fr)
WO (1) WO2000033838A1 (fr)
ZA (1) ZA200104398B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900232B2 (en) 2000-06-15 2005-05-31 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
ES2259047T3 (es) * 2000-10-24 2006-09-16 MERCK & CO., INC. Antagonista de receptor de integrina de la dibenzoxazepina.
CA2436130A1 (fr) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Indoles substitues et utilisation de ceux-ci comme antagonistes d'integrine
US6872730B2 (en) * 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
WO2004058760A1 (fr) 2002-12-20 2004-07-15 Pharmacia Corporation Composes de thiazole en tant que derives d'antagonistes des recepteurs de l'integrine
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
EP1841406A4 (fr) * 2004-12-21 2008-06-25 Smithkline Beecham Corp Procedes et formulations
SI2593452T1 (sl) 2010-07-14 2017-06-30 Novartis Ag Heterociklične spojine agonisti receptorja IP
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
WO2014125413A1 (fr) 2013-02-13 2014-08-21 Novartis Ag Composés hétérocycliques agonistes du récepteur ip
PT3929196T (pt) 2013-09-24 2023-09-11 Fujifilm Corp Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687154B1 (fr) * 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
PT910563E (pt) * 1995-06-29 2003-09-30 Smithkline Beecham Corp Antagonistas de receptores de integrina
AU4109297A (en) * 1996-09-27 1998-04-17 Merkler, H. Tank for liquids, particularly for chemically aggressive liquids
JP2001501951A (ja) 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション 骨形成刺激方法
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Also Published As

Publication number Publication date
UY25824A1 (es) 2001-07-31
AU754408B2 (en) 2002-11-14
UA71586C2 (en) 2004-12-15
HUP0104804A2 (hu) 2002-05-29
HK1042037B (zh) 2005-07-29
EP1146874A4 (fr) 2002-06-05
HK1042037A1 (en) 2002-08-02
ES2229798T3 (es) 2005-04-16
PT1146874E (pt) 2005-02-28
EP1146874B1 (fr) 2004-09-22
DE69920518D1 (de) 2004-10-28
MA25265A1 (fr) 2001-10-01
CO5150166A1 (es) 2002-04-29
ID28811A (id) 2001-07-05
HUP0104804A3 (en) 2002-12-28
CZ20011963A3 (cs) 2001-11-14
JP4481504B2 (ja) 2010-06-16
IL143390A (en) 2006-07-05
BR9915879A (pt) 2002-02-13
NO318895B1 (no) 2005-05-18
AP1534A (en) 2006-01-09
WO2000033838A1 (fr) 2000-06-15
BG65118B1 (bg) 2007-03-30
AR035006A1 (es) 2004-04-14
EG24025A (en) 2008-03-26
CA2353415A1 (fr) 2000-06-15
SK7452001A3 (en) 2001-12-03
EP1146874A1 (fr) 2001-10-24
NZ511876A (en) 2004-02-27
CN1147300C (zh) 2004-04-28
OA11724A (en) 2005-01-26
AU1750200A (en) 2000-06-26
JP2003523931A (ja) 2003-08-12
KR20010080669A (ko) 2001-08-22
IL143390A0 (en) 2002-04-21
ATE277043T1 (de) 2004-10-15
PL348702A1 (en) 2002-06-03
PL195973B1 (pl) 2007-11-30
ZA200104398B (en) 2002-05-29
DE69920518T2 (de) 2005-09-22
EA003254B1 (ru) 2003-02-27
TR200101654T2 (tr) 2002-03-21
KR100620485B1 (ko) 2006-09-13
SI1146874T1 (en) 2005-04-30
PE20001563A1 (es) 2001-02-09
EA200100618A1 (ru) 2001-12-24
US6495560B1 (en) 2002-12-17
NO20012732D0 (no) 2001-06-01
CN1334730A (zh) 2002-02-06
DK1146874T3 (da) 2005-01-31
NO20012732L (no) 2001-08-01
TW482673B (en) 2002-04-11
BG105651A (en) 2002-02-28

Similar Documents

Publication Publication Date Title
CH689805A8 (fr) Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr) Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2963A1 (fr) Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr) Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
DZ2891A1 (fr) Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26598A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur préparation et compositions pharmaceutiques les contenant
DZ3042A1 (fr) Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2880A1 (fr) Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.
DZ2198A1 (fr) Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
DZ3045A1 (fr) Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26514A1 (fr) Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2894A1 (fr) Compositions pharmaceutiques contenant des dérivésde pyridol Ä1,2-AÜpyrazine et procédé pour leur p réparation.
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
DZ2954A1 (fr) Antagoniste des recepteurs de vitronectine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
FR2773804B1 (fr) Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
DZ2155A1 (fr) Aazétidines, procédé pour leur préparation, et co mpositions pharmaceutiques les contenant.
MA26547A1 (fr) Composes nouveaux, antagonistes des recepteurs de vitronectine, et compositions pharmaceutiques les contenant.